Project Grant R43TR006372
Award Date 8/15/26
Completion Date 5/14/27
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Waltham, MA 02451, USA
Similar Awards
- Zaiput Flow Technologies LLC received a $275,000 Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an innovative, continuous crystallization device for pharmaceutical manufacturing. The goal is to improve the purification process of active pharmaceutical ingredients, which is a critical step used in over 90% of pharmaceutical production. The novel device aims to address scalability, cost, and...
- The National Center for Advancing Translational Sciences, under the Department of Health and Human Services National Institutes of Health, awarded Cascade Biocatalysts Inc. $306,871 on August 15, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop immobilized cofactor regeneration systems that accelerate enzymatic active pharmaceutical ingredient manufacturing. Cascade will design, synthesize, and evaluate immobilized cofactor-regeneration resins to expand...
- The National Institute of General Medical Sciences awarded Nirrin Technologies Inc. $1,156,172 as a Direct to Phase II Small Business Innovation Research (SBIR) Project Grant on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). Nirrin Technologies will integrate its high-precision tunable laser spectroscopy (HPTLS) technology into liquid chromatography workflows to enable simultaneous identification and quantification of biopharmaceutical formulation...
- The National Center for Advancing Translational Sciences at the National Institutes of Health awarded $931,463 to Acousticabio, Inc. on August 1, 2026, under SBIR Phase II funding (CFDA 93.350) to develop microgel-based formulations enabling subcutaneous delivery of monoclonal antibodies at ultra-high concentrations. Monoclonal antibodies currently require intravenous administration because their structural complexity and poor stability make high-concentration formulation difficult. IV...
- The National Center for Advancing Translational Sciences (NCATS) awarded Syntr Health Technologies, Inc., $2,050,527 on September 25, 2025, under the NCATS program (CFDA 93.350) to automate an FDA-cleared CD-microfluidic platform for rapid tissue microsizing. Syntr Health will develop device automation for its SYNTRFUGE system and SYNTRFPU360 platform to streamline tissue processing and dissociation. The technology processes multiple tissue types—including kidney, liver, brain, and breast cancer...
- The National Center for Advancing Translational Sciences awarded CFD Research Corporation $349,752 on August 17, 2026, under NCATS' translational science grant program (CFDA 93.350, NCATS program). The award funds development of the High-Throughput Organoid Platform for Electrophysiology Studies (HOPES)—an integrated, automated system for growing, maintaining, and screening brain organoids at high throughput using multi-electrode array (MEA) technology embedded in a microphysiological system...
- The National Institute of Standards and Technology awarded Zymosense Inc. a $800,000 Cooperative Agreement under the Science, Technology, Business and/or Education Outreach federal grant program (CFDA 11.620) for the period of September 1, 2022 through August 31, 2024. Under this award, Zymosense will optimize its automated pipetting screening tool for assessing single-walled carbon nanotube dispersion and separation processes. In Phase I, the company demonstrated the feasibility of using the...
- Federal Grant Award Summary Millennial Materials & Devices Inc. received a $306,872 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on August 1, 2025, with a completion date of July 31, 2026. The company is developing a 3D printed integrated sample preparation and chromatography platform designed to process limited-volume complex biological samples for proteomics research. The platform utilizes custom 3D printable carbon microbead...
- The National Center for Advancing Translational Sciences awarded The Washington University $427,625 on May 1, 2026, under the NCATS program (CFDA 93.350) to develop a modular biomanufacturing and cryopreservation platform for scalable production of clinical-grade human induced pluripotent stem cell (hiPSC) therapies. The award funds development of a low-shear, perfusion-based bioreactor system coupled with controlled-rate cryopreservation to address manufacturing bottlenecks in hiPSC therapeutic...
- The National Science Foundation awarded Noara Therapeutics Corp. $305,000 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop design strategies that improve the efficacy, durability, and safety of RNA-based therapeutics. This Small Business Innovation Research Phase I project addresses the technical barrier that chemical modifications to RNA molecules, while enhancing stability and safety, can interfere with essential molecular functions and...